Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06289673 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

StatusRecruiting
PhasePhase 4
Started2024-12-26
View on ClinicalTrials.gov ↗

Amendment history

2026-07-13
Study Status, Contacts/Locations v16
Study sites3→5
2026-04-29
Study Status, Contacts/Locations v15
Study sitescontacts updated at 1 of 3 sites
2026-02-27
Study Status v14
Re-verified, no change to tracked fields
2025-09-22
Study Status, Contacts/Locations v13
Study sites2→3
2025-07-14
Study Status, Contacts/Locations v12
Study sites1→2
Show 11 earlier versions
2025-03-21
Study Status, Study Description v11
2025-02-26
Study Status, Eligibility v10
Eligibility criteria-32 characters
[...] study available, enrolled on competing trial, etc.). Note: theThe intention of this exclusion criterion is to only enroll participantsall whonewly maydiagnosed subsequentlyALL/ enrollLLy/ onMPAL an SJALL therapeutic trialpatients. If participant is screened as a potential participant for [...]
2025-01-10
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v9
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-01→confirmed 2024-12-26
Study sitesdetails revised at 1 of 1 site
2024-12-13
Study Status v8
Start date2024-12→2025-01
2024-11-07
Study Status v7
Start date2024-11→2024-12
2024-10-08
Study Status v6
Start date2024-10→2024-11
2024-08-16
Study Status v5
Start date2024-08→2024-10
2024-07-23
Study Status v4
Start date2024-07→2024-08
2024-06-17
Study Status v3
Start date2024-06→2024-07
2024-05-23
Study Status v2
Start date2024-05→2024-06
2024-03-14
Study Status, Eligibility v1
Eligibility criteria-7 characters
[...] is screened as a potential participant for subsequent SJALL trials and later found to be ineligible due to information obtaine [...]
2024-02-23
Original filing
The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies. * To develop a central database of genomic and clinical findings. Secondary Objectives * To assess event free and overall survival data of patients enrolled on this study.
Trial Details
NCT Number NCT06289673
Lead Sponsor St. Jude Children's Research Hospital
Conditions Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia
Enrollment 850 participants
Start Date 2024-12-26
Primary Completion 2034-05 (estimated)
Study Completion 2039-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-14